Addyi Restarting After Acute Illness: A Clinical Guide for Patients and Prescribers

Why Acute Illness Complicates Flibanserin Use

Acute illness forces a temporary stop of flibanserin in most patients, and that break resets the risk profile almost entirely. The reason is straightforward: flibanserin is a substrate of CYP3A4 and CYP2C19, and nearly every drug prescribed for a common infection, fever, or inflammatory episode can alter one or both of those pathways [2]. Add the CNS-depressant burden of illness itself, and the combination of continued flibanserin use and acute-illness pharmacotherapy becomes clinically unsafe.

What Happens to Flibanserin During Illness

Flibanserin has a short half-life of approximately 11 hours [2]. That means plasma concentrations drop to negligible levels within 48 to 72 hours of stopping the drug. There is no meaningful drug accumulation to "protect" a patient if she accidentally takes a dose while still on an interacting medication.

On the other side of that coin, stopping flibanserin does not produce withdrawal. HSDD symptoms may return, but there is no receptor down-regulation or physiological dependence that makes abrupt cessation dangerous [3]. Patients can stop, wait, and restart.

Which Illnesses Typically Require a Pause

Any condition requiring a CYP3A4 inhibitor, a CNS depressant, or a drug with significant hypotensive effects necessitates pausing flibanserin [2]. Practically, the most common scenarios are:

• Respiratory infections treated with azithromycin or clarithromycin
• Vaginal or systemic fungal infections treated with fluconazole or itraconazole
• Urinary tract infections treated with ciprofloxacin or metronidazole
• Fever or pain managed with antihistamine-containing combination products (e.g., NyQuil, Benadryl)
• Short courses of systemic corticosteroids, which can affect blood pressure unpredictably

The FDA-approved prescribing information for flibanserin explicitly lists strong and moderate CYP3A4 inhibitors as contraindicated or requiring caution [2]. Clarithromycin is a strong CYP3A4 inhibitor; a single five-day Z-pack course of azithromycin carries moderate inhibitory potential that resolves within 24 hours of the last dose [4].

The BEGONIA Trial: Understanding What You Are Restarting

Before addressing restart mechanics, it helps to anchor expectations to clinical trial data. The BEGONIA trial, published in the Journal of Sexual Medicine in 2014 (N=1,267), evaluated flibanserin 100 mg at bedtime versus placebo over 24 weeks in premenopausal women with generalized acquired HSDD [1]. Patients receiving flibanserin reported a statistically significant increase in the number of satisfying sexual events per 28 days compared to placebo (P<0.001), alongside improvements on the Female Sexual Function Index desire subscale [1].

Putting the Efficacy Data in Context

The absolute improvement in satisfying sexual events in BEGONIA was modest: approximately 0.5 to 1.0 additional events per 28-day period over placebo [1]. That number matters for restart counseling. Patients sometimes expect rapid re-establishment of benefit after restarting, but the original BEGONIA data and the broader phase-3 program suggest the full therapeutic response takes four to eight weeks to manifest [1][3].

A 2014 pooled analysis of three phase-3 trials (N=2,400) published in the Journal of Sexual Medicine confirmed that response rates plateau between weeks 4 and 8 in most responders [3]. Patients restarting after illness should be counseled to give the drug at least eight weeks before evaluating response.

Adverse Events Relevant to Restart

In the BEGONIA trial, the most frequently reported adverse events were dizziness (11.4% flibanserin vs. 2.9% placebo), somnolence (9.2% vs. 3.0%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 3.9%) [1]. These rates were measured in patients who had reached steady state. During a restart, when CNS reserve may already be reduced by recent illness, the same adverse events could occur at greater intensity. Prescribers should warn patients explicitly about this during the first two weeks.

Pharmacokinetic Rationale for Treating Restart Like a New Start

Flibanserin's CYP3A4 and CYP2C19 metabolism means its plasma level is highly sensitive to any enzyme-modulating drug taken during or after illness [2]. Because the half-life is only 11 hours, steady-state concentrations are reached within approximately 2.5 days of daily dosing. That also means any enzyme inhibitor introduced after restart will push concentrations upward rapidly.

CYP3A4 Inhibitor Washout Before Restart

The FDA-approved labeling requires that strong CYP3A4 inhibitors be stopped for at least two days before restarting flibanserin [2]. For moderate inhibitors, the guidance is less prescriptive, but standard pharmacokinetic reasoning supports waiting for five half-lives of the inhibitor. Clarithromycin (half-life approximately 6 hours) clears in 30 hours [4]. Fluconazole (half-life approximately 30 hours) requires roughly 6 to 7 days [5]. Itraconazole, which has a much longer active metabolite half-life, may require 14 or more days before CYP3A4 activity normalizes [5].

Prescribers should verify these specific clearance windows before authorizing a restart prescription under the REMS program.

OTC Medications Commonly Missed at Restart

Patients frequently overlook over-the-counter products taken during illness. Diphenhydramine, found in most OTC sleep aids and many cold-combination products, adds meaningful CNS depression when combined with flibanserin [6]. The FDA prescribing information lists CNS depressants as drugs requiring caution because of additive sedation and hypotension risk [2]. Patients should be specifically asked about diphenhydramine, doxylamine, and any product containing alcohol (including liquid cough syrups) before restart is authorized.

Antifungal creams applied vaginally (e.g., miconazole 2% cream) show negligible systemic absorption and do not require a flibanserin pause [5]. This distinction is worth communicating proactively because patients often assume all antifungals create an interaction.

The Restart Protocol: Step-by-Step Clinical Guidance

Restart readiness requires four confirmations before the patient resumes 100 mg at bedtime:

Step 1. Confirm Full Clinical Recovery

The patient should be afebrile for at least 24 hours without antipyretics, no longer experiencing significant fatigue or orthostatic symptoms, and back to her baseline blood pressure. Orthostatic hypotension from dehydration during illness can compound flibanserin's own hypotensive effect, which is why the FDA black-box warning specifically highlights conditions of low blood pressure as a risk factor [2]. Clinicians should document a seated and standing blood pressure at the restart visit if the illness involved significant fluid loss or vomiting.

Step 2. Confirm Interacting Drugs Are Cleared

Using the half-life windows above, verify that all contraindicated or cautionary drugs are cleared. Document this in the patient's chart. The Addyi REMS program does not require a separate restart enrollment, but prescribers are expected to confirm ongoing patient eligibility at each prescription issuance [2].

Step 3. Reconfirm Alcohol Counseling

Alcohol remains the single highest-risk interaction with flibanserin. The REMS program exists in part because of hypotension and syncope events observed when patients combined the two [2][7]. A 2016 crossover pharmacodynamic study (N=25) published as part of the FDA safety review found that the combination of flibanserin 100 mg and two standard alcoholic drinks produced orthostatic hypotension in 4 of 25 participants, compared to 0 of 25 on flibanserin alone [7]. After illness, when patients may feel they are "celebrating recovery" with a social drink, this risk is particularly worth reinforcing.

The FDA recommends patients avoid alcohol completely while taking flibanserin, but the approved labeling specifies that if alcohol is consumed, it should be at least two hours before the bedtime dose [2].

Step 4. Resume at the Standard Dose Without Dose Reduction

There is no approved lower-dose formulation of flibanserin. The drug comes only as a 100 mg tablet, and the full therapeutic dose is 100 mg at bedtime. Splitting tablets is not recommended because the tablet is not scored and there are no pharmacokinetic data supporting altered release from a split tablet [2]. If a prescriber is concerned about CNS adverse events in a patient restarting after illness, the practical mitigation is closer monitoring during the first two weeks, not dose reduction.

The American College of Obstetricians and Gynecologists (ACOG) notes in its committee opinion on female sexual dysfunction that shared decision-making about treatment continuation and restart is appropriate, with particular attention to the patient's overall medication burden and comorbidities [8].

Monitoring During the First Two Weeks Post-Restart

The highest-risk window for hypotension and syncope is the first two weeks of any flibanserin course, including restarts [2]. During this period, prescribers should advise patients to:

• Take the dose in bed, not while standing or preparing for bed
• Avoid rising quickly from a supine position for at least 30 minutes after taking the tablet
• Not drive or operate heavy machinery for at least eight hours after each dose
• Report any episode of lightheadedness, near-syncope, or frank syncope immediately

A 2020 systematic review in the Journal of Sexual Medicine (N=9 trials, 5,914 participants) confirmed that CNS adverse events were most concentrated in the first 30 days of flibanserin use across all trial arms [9]. This applies directly to restart scenarios.

When to Contact the Prescriber Before Restarting

Patients should contact their prescriber rather than self-restarting if any of the following are true:

• They were prescribed a new medication during the illness that they will continue long-term
• Their blood pressure was notably low or high during the illness
• They experienced syncope or presyncope during the illness, from any cause
• The illness lasted more than 10 days, suggesting a more complex clinical picture

Drug Interaction Table: Common Illness Medications and Flibanserin

| Illness Medication | Interaction Type | Action Required | |---|---|---| | Clarithromycin (Biaxin) | Strong CYP3A4 inhibitor | Contraindicated; wait 30 hours after last dose | | Azithromycin (Z-Pak) | Moderate CYP3A4 inhibitor | Wait 24 hours after last dose | | Fluconazole (Diflucan) | Strong CYP3A4 inhibitor | Wait 6-7 days after last dose [5] | | Ciprofloxacin (Cipro) | Moderate CYP3A4 inhibitor | Wait 24-48 hours after last dose | | Metronidazole (Flagyl) | Moderate CYP3A4 inhibitor | Wait 24 hours after last dose | | Diphenhydramine (Benadryl) | Additive CNS depression | Wait until fully cleared; do not overlap | | Alcohol-containing syrups | Additive CNS/BP depression | Do not overlap; allow 2 hours minimum | | Ibuprofen / acetaminophen | No significant interaction | May be continued as needed [6] | | Prednisone short course | Blood pressure variability | Resume flibanserin only after course ends | | Topical miconazole (vaginal) | Negligible systemic absorption | No pause required [5] |

Special Populations: What Changes the Restart Decision

Hepatic Impairment

Flibanserin is contraindicated in patients with any degree of hepatic impairment [2]. Acute illness sometimes involves transient liver enzyme elevations, particularly with viral infections or with acetaminophen use at high doses during fever. A liver function panel is reasonable before restarting flibanserin in any patient who experienced a prolonged febrile illness or who took more than 2 g of acetaminophen daily during the illness. The prescribing information specifies that hepatic impairment increases flibanserin exposure significantly, with AUC increasing up to 4.5-fold in moderate hepatic impairment compared to normal hepatic function [2].

Patients on Hormonal Contraceptives

Oral contraceptives containing ethinyl estradiol are weak CYP3A4 inhibitors and may modestly increase flibanserin plasma concentrations [2]. For patients who did not change their contraceptive method during the illness, this interaction is already accounted for in the baseline prescription. No additional adjustment is needed at restart unless a new hormonal contraceptive was started during the illness episode.

Patients Over 65 or Perimenopausal

Flibanserin is FDA-approved for premenopausal women only [2]. Perimenopausal patients whose HSDD diagnosis was established while they were still premenopausal occupy a gray zone. ACOG guidance suggests that sexual health interventions should be individualized and that off-label use requires careful documentation and informed consent [8]. Older patients who experienced orthostatic changes during illness face a higher restart risk and warrant a blood pressure check before resuming.

Reassessing HSDD Diagnosis at Restart

A period of illness sometimes gives patients and clinicians a natural opportunity to reassess whether the original HSDD diagnosis still applies. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) requires that symptoms be present for at least six months and cause marked distress or interpersonal difficulty [10]. A temporary reduction in sexual desire caused by acute illness does not meet that threshold.

If a patient reports that her desire returned spontaneously during recovery without flibanserin, that is clinically meaningful information. It may indicate that the original presentation was more situational than the DSM-5 requires for a generalized HSDD diagnosis, or it may reflect that a contributing factor (stress, fatigue) was transiently resolved during the rest period of illness. Either way, a brief structured reassessment using the Female Sexual Function Index or the Female Sexual Distress Scale-Revised is appropriate before writing a restart prescription [11].

The Female Sexual Distress Scale-Revised, validated in a sample of 400 women and published in the Journal of Sexual Medicine, requires a score of 11 or higher to confirm clinically significant sexual distress [11]. Prescribers can administer this in fewer than two minutes at the restart visit.

REMS Program Obligations at Restart

The Addyi REMS program requires that all prescribers and dispensing pharmacies be certified, and that patients receive a medication guide at each dispensing [2][12]. At restart, the pharmacy will dispense a new medication guide unless the patient presents a prescription within the same dispensing period. Prescribers should confirm their own REMS certification is current, as certifications must be renewed periodically [12]. Patients who filled their last prescription at a different pharmacy (for example, while traveling during illness) may need to confirm REMS certification at their new pharmacy before the prescription can be filled.

The FDA REMS database is maintained at the accessdata.fda.gov portal, and pharmacists can verify certification status there [12].

Patient Communication Script for Restart

Direct language reduces confusion at restart. A practical script for clinicians:

"You have recovered from your illness. Before we restart Addyi, I want to confirm three things. First, you have finished any antibiotic or antifungal we prescribed. Second, you are no longer taking any sleep aids that contain diphenhydramine. Third, you understand that alcohol and Addyi together can drop your blood pressure low enough to cause fainting. Take the first new pill in bed tonight. If you feel dizzy or faint at any point in the next two weeks, stop the medication and call us."

This language is consistent with the FDA prescribing information's counseling requirements and the REMS educational materials [2][12].